Hrt Financial LP Reata Pharmaceuticals Inc Transaction History

Hrt Financial LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$79.22 - $105.37 $584,326 - $777,209	7,376 Added 273.9%	10,069 $1.03 Million
Q1 2023 May 12, 2023	SELL	$30.85 - $93.17 $820,270 - $2.48 Million	-26,589 Reduced 90.8%	2,693 $244,000
Q4 2022 Feb 10, 2023	SELL	$22.15 - $42.11 $244,425 - $464,683	-11,035 Reduced 27.37%	29,282 $1.11 Million
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $782,552 - $1.47 Million	40,317 New	40,317 $1.01 Million
Q2 2021 Aug 16, 2021	SELL	$78.27 - $151.29 $388,297 - $750,549	-4,961 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$94.25 - $132.81 $467,574 - $658,870	4,961 New	4,961 $494,000
Q4 2020 Feb 16, 2021	SELL	$102.03 - $184.62 $1.3 Million - $2.36 Million	-12,767 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$93.53 - $163.34 $530,128 - $925,811	5,668 Added 79.84%	12,767 $1.24 Million
Q2 2020 Aug 14, 2020	BUY	$126.3 - $176.56 $670,400 - $937,180	5,308 Added 296.37%	7,099 $1.11 Million
Q1 2020 May 15, 2020	BUY	$124.16 - $247.74 $222,370 - $443,702	1,791 New	1,791 $258,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.